CDT Equity Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that the Company received a written notice ("Notice") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. AstraZeneca PLC is among the best cancer stocks on this list. TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent […]
Sarborg announced that the patent was developed using its proprietary Signature Agent and Multi-Agent platform, supported by its Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database. According to
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 -- CDT Equity Inc. , today notes the announcement from Sarborg Limited regarding the filing of a new Substance of Matter patent covering...
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
CDT Equity moves higher ahead of earnings, recovering from last week's decline tied to delayed SEC filing and expectations of wider net losses.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Let's have a look at the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 375.0K | $2.81K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-11-12 | — | — | — |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CDT | -53.98% | -93.29% | -96.75% | -99.84% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -56.95% | -88.65% | -93.31% | -112.53% |